Genes May Leave Some People More Vulnerable to Severe Covid-19
By Carl Zimmer,
The New York Times
| 06. 03. 2020
Geneticists have turned up intriguing links between DNA and the disease. Patients with Type A blood, for example, seem to be at greater risk.
Why do some people infected with the coronavirus suffer only mild symptoms, while others become deathly ill?
Geneticists have been scouring our DNA for clues. Now, a study by European scientists is the first to document a strong statistical link between genetic variations and Covid-19, the illness caused by the coronavirus.
Variations at two spots in the human genome are associated with an increased risk of respiratory failure in patients with Covid-19, the researchers found. One of these spots includes the gene that determines blood types.
Having Type A blood was linked to a 50 percent increase in the likelihood that a patient would need to get oxygen or to go on a ventilator, according to the new study.
The study was equally striking for the genes that failed to turn up. The coronavirus attaches to a protein called ACE2 on the surface of human cells in order to enter them, for example. But genetic variants in ACE2 did not appear to make a difference in the risk of severe Covid-19.
The findings suggest that relatively unexplored factors...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...
